



CURRICULUM VITAE (CVA)

Part A. PERSONAL INFORMATION

CV date

30/11/2021

First name	Eva María		
Family name	Verdugo Sivianes		
Gender (*)	Female	Birth date (dd/mm/yyyy)	07/11/1990
ID number	28817571-C		
e-mail	everdugo-ibis@us.es		
Open Researcher and Contributor ID (ORCID) (*)	0000-0002-0922-0371		

A.1. Current position

Position	Postdoctoral researcher		
Initial date	19/06/2020		
Institution	FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA		
Department/Center	Biología molecular del cáncer / Instituto de Biomedicina de Sevilla (IBIS)		
Country	Spain	Teleph. number	(0034) 955 923 110
Key words	Molecular biology, cell biology, cancer, cell culture, animal models		

A.2. Previous positions (research activity interruptions, art. 14.2.b))

Period	Position/Institution/Country/Interruption cause
2017-2020	Predoctoral / CIBERONC
2017-2018	Predoctoral / FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
2014	RTICC Fellowship (Red temática para la investigación cooperativa en cáncer)
2013	IFIMAV Fellowship (Fundación Marqués de Valdecilla)

A.3. Education

PhD, Licensed, Graduate	University/Country	Year
Specialization Postgraduate Degree in Bioinformatic Analysis	Pablo de Olavide University	2020
PhD in Molecular Biology, Biomedical and Clinical Research	University of Seville	2019
Master's Degree in Biomedical Research	University of Seville	2014
Bachelor's Degree in Biotechnology	Pablo de Olavide University	2013

Part B. CV SUMMARY (max. 5000 characters, including spaces)

Eva M^a Verdugo Sivianes carried out her PhD in Molecular Biology, Biomedicine and Clinical Research from the University of Seville under the supervision of Dr. Amancio Carnero at the Biomedicine Institute of Seville in December 2019 with honors "Cum laude". Eva has a Bachelor's Degree in Biotechnology from Pablo de Olavide University since July 2013, a Master's Degree in Biomedical Research from the University of Seville since September 2014 and the Specialization Degree in Bioinformatic Analysis from Pablo de Olavide University since October 2020.

During her PhD, she has participated in different publications in international journals, several posters at various national and international conferences and some research projects of the group. Eva has both certificates of competence of animal welfare in animals used for experimentation and other scientific purposes (Category B and C) and the Certificate in Advanced English (CAE). Eva is a member of the ASEICA and EACR associations, as well as the thematic network CIBERONC, where she has been part of the Organizing Committee of the III Meeting of Young Researchers in 2020. Eva currently works as a postdoctoral researcher in the same group where she participates in different collaborative projects.

Part C. RELEVANT MERITS (sorted by typology)

C.1. Publications

1. **Verdugo-Sivianes EM**, Carnero A. *Role of the Holoenzyme PP1-SPN in the Dephosphorylation of the RB Family of Tumor Suppressors During Cell Cycle*. *Cancers* (Basel). 2021 May 6;13(9):2226. doi: 10.3390/cancers13092226.
2. **Verdugo-Sivianes EM**, Rojas AM, Muñoz-Galvan S, Otero-Albiol D, Carnero A. *Mutation of SPINOPHILIN (PPP1R9B) found in human tumors promotes the tumorigenic and stemness properties of cells*. *Theranostics*. 2021 Jan 19;11(7):3452-3471. doi: 10.7150/thno.53572.
3. Perez-Martinez L, Romero L, Muñoz-Galvan S, **Verdugo-Sivianes EM**, Rubio-Mediavilla S, Otero JA, Carnero A, Blanco JR. *Implications of Maraviroc and/or Rapamycin in a Mouse Model of Fragility*. *Aging*. 2020 Apr 30;12(9):8565-8582. doi: 10.18632/aging.103167.
4. Muñoz-Galván S, Felipe-Abrio B, **Verdugo-Sivianes EM**, Perez M, Jiménez-García MP, Suarez-Martinez E, Estevez-Garcia P, Carnero A. *Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness*. *Molecular Cancer*. 2020 Jan 11;19(1):7. doi: 10.1186/s12943-020-1130-z.
5. Muñoz-Galvan S; Felipe-Abrio B; García-Carrasco M; Dominguez-Piñol J; Suarez-Martinez E; **Verdugo-Sivianes EM**; Espinosa-Sanchez A; Navas LE; Otero-Albiol D; Marin JJ; Jimenez-Garcia MP; Garcia-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A. *New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools*. *Journal of Experimental and Clinical Cancer Research*. 2019 Jun 3;38(1):234. doi: 10.1186/s13046-019-1245-5.
6. Felipe-Abrio B; **Verdugo-Sivianes EM**; Carnero A. *c-MYB- and PGC1a-dependent metabolic switch induced by MYBBP1A loss in renal cancer*. *Molecular Oncology*. 2019 Jul;13(7):1519-1533. doi: 10.1002/1878-0261.12499.
7. Felipe-Abrio B; **Verdugo-Sivianes EM**; Saez C; Carnero A. *Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer*. *Cancers* (Basel). 2019 Feb 18;11(2):235. doi: 10.3390/cancers11020235.
8. **Verdugo-Sivianes EM**; Navas L; Molina-Pinelo S; Ferrer I; Quintanal-Villalonga A; Peinado J; Garcia-Heredia JM; Felipe-Abrio B; Muñoz-Galvan S; Marin JJ; Montuenga L; Paz-Ares L; Carnero A. *Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer*. *Oncotarget*. 2017 Oct 26;8(62):105196 - 105210. doi: 10.18632/oncotarget.22111.
9. Garcia-Heredia JM; Lucena-Cacace A; **Verdugo-Sivianes EM**; Perez M; Carnero A. *The cargo protein MAP17 (PDZK1IP1) regulates the cancer stem cell pool activating the Notch pathway by abducting NUMB*. *Clinical Cancer Research*. 2017 Jul 15;23(14):3871-3883. doi: 10.1158/1078-0432.CCR-16-2358.
10. Jimenez-Garcia MP; **Verdugo-Sivianes EM**; Lucena-Cacace A. *Nicotinamide Adenine Dinucleotide+ Metabolism Biomarkers in Malignant Gliomas*. *Cancer Translational Medicine*. 2016 Dic, 2 - 6, pp. 189 – 196.
11. Garcia-Heredia JM; **Verdugo Sivianes EM**; Lucena-Cacace A; Molina-Pinelo S; Carnero A. *Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy*. *Oncotarget*. 2016 Sep 27;7(39):63611-63628. doi: 10.18632/oncotarget.11553.
12. Ferrer I; **Verdugo-Sivianes EM**; Castilla MA; Melendez R; Marin JJ; Muñoz-Galvan S; Lopez-Guerra JL; Vieites B; Ortiz-Gordillo MJ; De Leon JM; Praena-Fernandez JM; Perez M; Palacios J; Carnero A. *Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors*. *Oncogene*. 2016 May;35(21):2777-88. doi: 10.1038/onc.2015.341.
13. Lopez-Guerra JL; **Verdugo-Sivianes EM**; Otero-Albiol D; Vieites B; Ortiz-Gordillo MJ; De Leon JM; Praena-Fernandez JM; Marin JJ; Carnero A. *High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer*. *Oncotarget*. 2015 Oct 6;6(30):30343-56. doi: 10.18632/oncotarget.4850.

C.2. Congress (participations with posters)

1. **Verdugo-Sivianes EM**, Rojas AM, Espinosa-Sanchez A, Muñoz-Galvan S, Otero-Albiol D, Navas LE, Suarez-Martinez E, Sanchez-Diaz L, Garcia-Heredia JM, Carnero A. *Relevance of the interaction between SPN and PP1 in tumorigenesis*. 27th Congress of the European Association for cancer research (EACR2021). 09-12/06/2021.

2. Espinosa-Sanchez A, **Verdugo-Sivianes EM**, Muñoz-Galvan S, Navas LE, Suarez-Martinez E, Sanchez-Diaz L, Otero-Albiol D, Clemente-Garcia C, Vazquez-Gutierrez I, Carnero A. *PAPPA, a new interacting protein of the tumor suppressor SPN, with a role in tumorigenesis*. 27th Congress of the European Association for cancer research (EACR2021). 09-12/06/2021.
3. Muñoz-Galvan S, Felipe-Abrio B, **Verdugo-Sivianes EM**, Perez M, Jimenez-Garcia MP, Suarez-Martinez E, Estevez-Garcia P, Carnero A. *Downregulation of MYPT increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness*. 27th Congress of the European Association for cancer research (EACR2021). 09-12/06/2021.
4. **Verdugo-Sivianes EM**, Felipe-Abrio B, Otero-Albiol D, Jiménez-García MP, Navas L, Peinado-Serrano J, Munoz-Galván S, Perez M, García-Heredia JM, Carnero A. (2018). *Prognostic relevance of PP1 in breast cancer*. 25th Biennial Congress of the European Association for Cancer Research (EACR). Amsterdam (Holland). 30/06/2018-03/07/2018.
5. Otero-Albiol D, Munoz-Galvan S, Suarez-Martínez E, **Verdugo-Sivianes EM**, Jiménez-García MP, Navas L, Perez M, García-Heredia JM, Peinado-Serrano J, Carnero A. (2018). *Hypoxia-induced PLD2 promotes tumorigenesis and stem cell-like properties in tumor cells*. 25th Biennial Congress of the European Association for Cancer Research (EACR). Amsterdam (Holland). 30/06/2018-03/07/2018.
6. Muñoz-Galván S, Felipe-Abrio B, **Verdugo-Sivianes EM**, Jiménez-García MP, Suarez-Martinez E, Perez M, Otero-Albiol D, Peinado-Serrano J, Navas L, Carnero A. (2018). *Downregulation of MYPT1 increases tumorigenesis and resistance to platinum drugs in ovarian cancer*. 25th Biennial Congress of the European Association for Cancer Research (EACR). Amsterdam (Holland). 30/06/2018-03/07/2018.
7. Jiménez-García MP, Lucena-Cacace A, Robles-Frías MJ, Felipe-Abrio B, **Verdugo-Sivianes EM**, Otero-Albiol D, Peinado-Serrano J, Perez M, Munoz-Galván S, Garcia-Heredia JM, Narlik-Grassow M, Blanco-Aparicio C, Carnero A (2016). *Conditional transgenic expression of PIM1/PIM2 kinases in hormone-dependent tissues induces mammary gland and female reproductive system tumors*. 24th Biennial Congress of the European Association for Cancer Research (EACR). Manchester (UK). 09-12/07/2016
8. Jiménez-García MP, Lucena-Cacace A, Robles-Frías MJ, Felipe-Abrio B, **Verdugo-Sivianes EM**, Otero-Albiol D, Peinado-Serrano J, Perez M, Munoz-Galván S, Garcia-Heredia JM, Narlik-Grassow M, Blanco-Aparicio C, Carnero A (2016). *Determination of the Proto-Oncogenic Role of PIM1/PIM2 Kinases in Male Reproductive System Pre-Neoplastic lesions by using Conditional Transgenic Murine Models*. 24th Biennial Congress of the European Association for Cancer Research (EACR). Manchester (UK). 09-12/07/2016
9. Felipe-Abrio B, Jiménez-García MP, **Verdugo-Sivianes EM**, Lucena-Cacace A, Otero-Albiol D, Perez M, Peinado-Serrano J, Munoz-Galván S, Garcia-Heredia JM, Carnero A (2016). *Absence of MYBBP1a translocation from nucleolus to nucleoplasm under glucose starvation in renal carcinoma cell lines*. 24th Biennial Congress of the European Association for Cancer Research (EACR). Manchester (UK). 09-12/07/2016
10. Lucena-Cacace A, Jiménez-García MP, Ferrer I, Felipe-Abrio B, **Verdugo-Sivianes EM**, Otero-Albiol D, Perez M, Munoz-Galván S, Garcia-Heredia JM, Peinado-Serrano J, Marín JJ, Narlik-Grassow M, Blanco-Aparicio C, Carnero A (2016). *Determination of the Proto-Oncogenic Role of PIM1/PIM2 Kinases in Male Reproductive System Pre-Neoplastic lesions by using Conditional Transgenic Murine Models*. 57th American Association for Cancer Research (AACR) Annual Meeting. New Orleans, LA (USA). 16-20/04/2016
11. Ferrer I, **Verdugo-Sivianes EM**, Castilla MA, Melendez R, Marin JJ, Muñoz-Galvan S, Lopez-Guerra JL, Vieites B, Ortiz-Gordillo MJ, De León JM, Praena-Fernandez JM, Perez M, Palacios J, Carnero A. *Loss of the tumor suppressor Spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors*. XV ASEICA International Congress, 2015. Seville (Spain). 21-23/10/2015

12. Jiménez-García MP, Ferrer I, Felipe-Abrio B, Lucena-Cacace A, **Verdugo-Sivianes EM**, Otero-Albiol D, Peinado-Serrano J, Perez M, Munoz-Galván S, Garcia-Heredia JM, Marin JJ, Narlik-Grassow M, Blanco-Aparicio C, Carnero A (2015). *Determination of the Proto-Oncogenic Role of PIM1/PIM2 Kinases in Male Reproductive System Tumors by using Conditional Transgenic Murine Models*. XV ASEICA International Congress, 2015. Seville (Spain). 21-23/10/2015
13. Jiménez-García MP, Ferrer I, Felipe-Abrio B, Lucena-Cacace A, **Verdugo-Sivianes EM**, Otero-Albiol D, Peinado-Serrano J, Perez M, Munoz-Galván S, Garcia-Heredia JM, Marin JJ, Narlik-Grassow M, Blanco-Aparicio C, Carnero A (2015). *Conditional Transgenic Expression of PIM1/PIM2 Kinases in Hormone-Dependent Tissues Induces Mammary Gland Tumors*. XV ASEICA International Congress, 2015. Seville (Spain). 21-23/10/2015
14. Perez M, Muñoz Galvan S, Jiménez-García MP, Marin JJ, Padillo J, Marín-Gómez LM, Garcia-Carbonero R, **Verdugo-Sivianes EM**, García-Heredia Jose M, Lucena-Cacace A, Felipe-Abrio B, Otero-Albiol D, Robles-Frias MJ, Carnero A (2015). *Orthotopic xenografts of colorectal hepatic metastases maintain morphological phenotypic and genetic characteristic of the original tumors*. XV ASEICA International Congress, 2015. Seville (Spain). 21-23/10/2015
15. Perez M, Muñoz Galvan S, Jiménez-García MP, Marin JJ, **Verdugo-Sivianes EM**, Garcia-Heredia Jose M, Lucena-Cacace A, Felipe-Abrio B, Otero-Albiol D, Carnero A. (2015). *Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 mRNA*. XV ASEICA International Congress, 2015. Seville (Spain). 21-23/10/2015
16. Ferrer I, **Verdugo-Sivianes EM**, Castilla MA, Melendez R, Marin JJ, Muñoz-Galvan S, Lopez-Guerra JL, Vieites B, Ortiz-Gordillo MJ, De León JM, Praena-Fernandez JM, Perez M, Palacios J, Carnero A. *Loss of the tumor suppressor Spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors*. 18th ECCO-40th ESMO European Cancer Congress 2015. Vienna (Austria) 25-29/09/2015

C.3. Research projects

1. Project name: **Identification of the mechanisms of dedifferentiation of tumor cells towards cancer stem cells. Role of tumor evolution and resistance to cancer therapy**. Main investigators: Amancio Carnero Moya. Funding entity: Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (P18-RT-2501). Duration: 01/01/2020 - 31/12/2023
2. Project name: **Mechanism of dedifferentiation to cancer stem cells and resistance to cancer therapy**. Main investigator: Amancio Carnero Moya. Funding entity: Ministerio de Ciencia, Innovación y Universidades (RTI2018-097455-B-I00). Duration: 01/01/2019 - 31/12/2021
3. Project name: **CIBER de Cáncer (CIBERONC)**. Main investigator: Amancio Carnero Moya. Funding entity: Instituto de Salud Carlos III, CIBER (RD16/12/00275). Duration: 01/01/2017 - 31/12/2022
4. Project name: **Definition of key mechanisms of multidrug resistance of head tumors and neck to chemo- and radiotherapy treatments. Identification of new individualized antitumor drugs**. Main investigators: Ángel Carracedo Álvarez; Matilde Lleona Pajarín; Amancio Carnero Moya. Funding entity: AECC (Spanish Association Against Cancer). Duration: 01/01/2017 - 31/12/2022
5. Project name: **Identification and characterization of genetic and physiological factors involved in cellular senescence. Clinical relevance in cancer**. Entity of realization: Biomedicine Institute of Seville (IBiS). Main investigator: Amancio Carnero Moya. Funding entity: FIS, Ministry of Economy and Competitiveness (PI15/00045). Duration: 01/01/2016 - 31/12/2018
6. Project name: **Immortalization and hypoxia connexion. Contribution to cancer**. Entity of realization: Biomedicine Institute of Seville (IBiS). Main investigator: Amancio Carnero Moya. Funding entity: BBVA Foundation. Duration: 01/01/2016 - 31/12/2018
7. Project name: **Evaluation of new therapeutic strategies for lung cancer with KRAS mutated by using xenografted animal models with human tumors**. Entity of realization: Biomedicine Institute of Seville (IBiS). Entity of realization: Biomedicine Institute of Seville (IBiS). Main investigator: Irene Ferrer Sánchez. Funding entity: Department of Health of the Andalusian Government (PI-0029-2013). Duration: 01/01/2014 - 31/12/2016